Return of the megarounds; Nvidia’s AI pitch to biotech; Bayer’s shakeup reaches the top; AstraZeneca buys into radiopharma; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

In case you missed it, we launched our latest newsletter this week. Post-Hoc, as we call it, is a weekly(ish) piece of analysis that follows big news, an insight from the journalist who broke the story, or a perspective that’s crucial to understanding events shaping biopharma and healthcare. Learn more and sign up for it here.

Return of the megarounds

Megarounds are back. As Kyle LaHucik writes, $100 million-plus financings are picking up at a pace that could approach the market’s peak three years ago. This week alone offered four examples: $150 million…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks